All Updates

All Updates

icon
Filter
Partnerships
Akili and Roblox partner to link ADHD therapy and gaming platform
Mental Health Tech
May 27, 2022
This week:
Partnerships
Intuitive AI partner with Moda Center to implement Oscar Sort recycling technology
Waste Recovery & Management Tech
Yesterday
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Mental Health Tech

Mental Health Tech

May 27, 2022

Akili and Roblox partner to link ADHD therapy and gaming platform

Partnerships

  • Digital therapeutics (DTx) company Akili Interactive Labs has agreed to a deal with global gaming platform Roblox that will result in Akili’s DTx solution for attention-deficit/hyperactivity disorder (ADHD) being hosted on the latter’s gaming platform. 

  • Roblox has developed an online space where users can play games that are created by developers and other users. Initially, through the partnership, children using EndeavorRx for ADHD treatment will be able to redeem rewards on Roblox for using the DTx. Future integrations of the two platforms are being investigated by the companies. 

  • EndeavorRx, Akili’s FDA and European Medicines Agency (EMA)-approved prescription-based DTx solution, is used to treat children between 8 to 12 years of age that show primarily inattentive or combined-type ADHD. EndeavorRx is typically used along with other therapeutic treatments such as medication, education, and clinician-directed therapy.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.